9th Jul 2015 06:42
LONDON (Alliance News) - FTSE 100-listed drugmaker AstraZeneca PLC on Thursday said it has entered an agreement with Tillotts Pharma AG, a unit of Japanese pharmaceutical company Zeria Group, to sell the non-US sales and development rights to its Entocort product.
Entocort is a gastroenterology medicine for patients with mild to moderate Crohn's disease and ulcerative colitis and generated sales of USD53 million outside of the US in 2014, Astra said.
Tillott will pay Astra USD215 million upon completion of the deal.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca